anti-inflammatoty and immuno-therapy for COVID-19 - live meta-analysis of clinical studies

Table Graph

anti-inflammatoty and immuno-therapy - versus control - for COVID 19 hospitalized pdf xlsx method abbreviations

Outcome	Relative effect 95%CI	Trt. better when	I2	k (RCT/OBS)	Bayesian probability	Overall ROB	Publication bias	Degree of certainty	Endpoint importance	Published MA
efficacy endpoints 00
deaths	0.92 [0.83, 1.01]	< 1	8%	23 studies (23/-)	96.3 %	some concern	low	moderate	crucial	-
deaths (time to event analysis only)	0.93 [0.47, 1.85]	< 1	0%	1 study (1/-)	58.2 %	low	not evaluable	high	crucial	-
clinical deterioration	0.68 [0.52, 0.89]	< 1	21%	7 studies (7/-)	99.8 %	some concern	not evaluable	moderate	important	-
clinical improvement	1.17 [1.02, 1.36]	> 1	36%	11 studies (11/-)	98.5 %	some concern	low	moderate	important	-
clinical improvement (14-day)	1.16 [0.84, 1.60]	> 1	0%	2 studies (2/-)	81.0 %	some concern	not evaluable	moderate	important	-
clinical improvement (28-day)	1.23 [0.87, 1.74]	> 1	0%	2 studies (2/-)	88.1 %	some concern	not evaluable	moderate	important	-
clinical improvement (7-day)	0.85 [0.56, 1.29]	> 1	0%	1 study (1/-)	22.3 %	low	not evaluable	high	important	-
clinical improvement (time to event analysis only)	1.79 [0.63, 5.11]	> 1	79%	2 studies (2/-)	86.3 %	some concern	not evaluable	moderate	important	-
death or ventilation	0.81 [0.60, 1.07]	< 1	34%	6 studies (6/-)	93.0 %	some concern	serious	moderate	important	-
hospital discharge	1.09 [1.01, 1.18]	> 1	7%	4 studies (4/-)	98.8 %	some concern	not evaluable	moderate	important	-
ventilation	0.90 [0.54, 1.51]	< 1	0%	5 studies (5/-)	64.9 %	some concern	not evaluable	moderate	important	-
ICU admission	0.43 [0.20, 0.96]	< 1	58%	5 studies (5/-)	98.0 %	some concern	not evaluable	moderate	non important	-
time to recovery	1.06 [0.77, 1.46]	> 1	0%	1 study (1/-)	63.8 %	low	not evaluable	high	non important	-
safety endpoints 00
serious adverse events	1.21 [0.75, 1.95]	< 1	4%	5 studies (5/-)	21.7 %	some concern	not evaluable	moderate	important	-
superinfection	0.79 [0.56, 1.11]	< 1	0%	2 studies (2/-)	91.1 %	some concern	not evaluable	moderate	important	-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.

anti-inflammatoty and immuno-therapy - versus control - for COVID 19 hospitalized pdf xlsx method abbreviations

efficacy endpoints 00

safety endpoints 00